Printer Friendly

Conserved Genetic Findings in Metastatic Bladder Cancer.

A Possible Utility of Allelic Loss of Chromosomes 9p21 and 17p13 in Diagnosis

It is estimated that 54 300 new cases of bladder carcinoma will be diagnosed and 12 400 people will die of bladder cancer in the United States in 2001.[2] Progressive growth of distant metastases is responsible for the majority of cancer-related deaths. Very little is known about the molecular mechanisms underlying the metastatic progression of bladder cancer Recent advances in tissue microdissection techniques permit the selective procurement of tumor cell populations from paraffin-embedded archival material for genetic analysis. Molecular analysis of microsatellite alterations of biologically distinct tumor cell subpopulations from the same patient may aid in the determination of tumor origin and further our understanding of the genetic basis of cancer progression.

Chromosome region 9p21 contains a tumor suppressor gene locus p16. p16 protein binds to cyclin-dependent kinase 4 (CDK4) and inhibits its interaction with cyclin D, subsequently leading to cell cycle arrest at the late G1 stage. A high frequency of allelic loss on chromosome 9p21 was observed in bladder cancer, implicating that p16 gene deletion may play an important role in the carcinogenesis and progression of bladder cancer.[2,3] Similarly, p53 gene alterations are frequently encountered in different stages of bladder cancer development.[4-7] In this study, we analyzed the pattern of allelic loss in these regions in 9 matched primary and metastatic bladder tumors.

MATERIALS AND METHODS

We studied 9 patients who had undergone radical cystectomy and bilateral lymphadenectomy between 1992 and 1995. All patients had regional lymph node metastases at the time of surgery. Patients ranged in age from 51 to 86 years (mean, 66 years). Grading of the primary tumor was performed according to the 1998 World Health Organization/International Society of Urologic Pathology classification.[8] The 1997 TNM system was used for pathologic staging.[9] Genomic DNA was prepared from primary cancers and matched synchronous lymph node metastases using a microdissection method.[10,11] Normal control DNA was prepared from uninvolved lymph nodes in all cases. The following oligonucleotide primer pairs for the microsatellite DNA markers were used: D9S161, D9S171, IFNA, and TP53 (Research Genetics, Huntsville, Ala).[12] Polymerase chain reaction amplification and gel electrophoresis were performed as previously described.[10,11] The criterion for allelic loss was complete or nearly complete absence of 1 allele in tumor DNA, as defined by direct visualization.[10,11] Polymerase chain reactions for each polymorphic micro-satellite marker were repeated at least twice from the same DNA preparations, and the same results were obtained.

RESULTS

The frequency of allelic loss in the primary cancer was 86% with D9S161, 67% with D9S171, 71% with IFNA, and 80% with TP53. The frequency of allelic loss in matched metastatic cancer was 100% with D9S161, 62% with D9S171, 71% with IFNA, and 80% with TP53. The overall frequency of allelic loss was 78% in primary cancer and 89% in paired metastatic cancer. An identical pattern of allelic imbalance (allelic loss or retention) at multiple DNA loci was observed in matched primary and metastatic carcinoma in 8 (89%) of 9 cases (Table, Figure). For example, case 5 showed loss of the same allele in primary cancer and matched metastases at all 4 marker loci (D9S161, D9S171, IFNA, and TP53). One case (case 1) showed allelic loss in the metastasis, but not in the primary cancer.
Comparison of Allelic Loss Pattern in Matched Cases of
Primary and Metastatic Bladder Cancer From 9 Patients

 Grader Stage([double
Case No. Tumor(*) Age, y/Sex ([dagger]) dagger])

 1 P 52/M High pT3
 M
 2 P 51/M High pT3
 M
 3 P 72/M High pT2b
 M
 4 P 65/M High pT2b
 M
 5 P 86/F High pT3
 M
 6 P 57/M High pT3
 M
 7 P 77/F High pT2b
 M
 8 P 68/M High pT3
 M
 9 P 57/M High pT3
 M

 Allelic Loss([sections])

Case No. Tumor(*) D9S161 D9S171 IFNA TP53

 1 P NL NL NL NL
 M 1 NL NL NL
 2 P 2 1 2 NI
 M 2 1 2 NI
 3 P 1 NL NL 1
 M 1 NL NL 1
 4 P 1 1 1 2
 M 1 NE 1 2
 5 P 2 2 2 1
 M 2 2 2 1
 6 P NI 1 2 NI
 M NI 1 2 NI
 7 P 2 2 NI NI
 M 2 2 NI NI
 8 P NI NL NI NI
 M NI NL NI NI
 9 P 2 2 2 2
 M 2 2 2 2

(*) P and M designate primary and synchronous lymph node metastases,
respectively, from the same patients.

([dagger]) Grading of the primary bladder cancer was performed
according to the 1998 World Health Organization/International
Society of Urologic Pathology classification system.

([double dagger]) Staging was performed according to the 1997
TNM staging system.

([sections]) 1 indicates loss of upper allele; 2, loss of lower
allele; NL, no loss of alleles; NI, noninformative; and NE, not
able to be evaluated.


[ILLUSTRATION OMITTED]

COMMENT

Detailed characterization and comparison of genetic alterations of biologically distinct tumor cell subpopulations may provide information about progression and clonal evolution of bladder cancer. In this study, we analyzed the pattern of allelic loss with polymorphic microsatellite markers (D9S104, D9S161, D9S171, and IFNA) on chromosome 9p21, which contains putative tumor suppressor gene p16 and on chromosome 17p13 (TP53), which contains p53 gene in matched primary and metastatic bladder tumors from 9 patients. We found an identical pattern of allelic loss in matched primary and metastatic carcinoma from the same patient, suggesting allelic loss of these chromosome regions occurred prior to metastatic progression. The relative constancy of these genetic changes in primary bladder cancer and paired metastatic lesions may aid in diagnosis and identification of tumor origins in difficult cases.

Previously, we compared the pattern of allelic loss in primary tumor and matched synchronous lymph node metastasis from prostate cancer.[13] A heterogenous pattern of allelic loss was observed. Forty-two percent of cases showed discordant allelic loss of microsatellite DNA markers on chromosome 8p12-21, 8p22, and 17q21 in primary tumor and matched lymph node metastasis.[13] Molecular analysis of whole mount sections from entirely embedded prostate glands have confirmed that separate tumors from the same patient have multiclonal (independent) origin.[11,14] However, molecular studies of multiple separate foci of bladder carcinoma suggest a monoclonal origin of the tumor.[15]

Miyao et al[16] studied 14 patients with lymph node metastases from bladder cancer and found complete concordance between genetic defects in the primary and metastatic sites. Loss of heterogeneity at chromosome 9 was seen in 64% of cases, and loss of heterogeneity at 17p was observed in 78% of cases. However, the pattern of allelic loss (upper or lower allele loss) was not reported.[16] Orlow et al[2] reported a lower incidence of genetic alterations (18%) at the p16 gene locus in chromosome 9p21 in a large cohort of bladder tumors. The discrepant results among different studies may be attributed to differences in the selection of polymorphic microsatellite markers, tissue microdissection techniques, tumor stage, and patient populations.

Our data indicated that the pattern of allelic loss at chromosome 9p21 (p16) and 17p13 (p53) in primary bladder cancer was generally maintained during cancer progression to metastasis, and an identical pattern of allelic loss in primary cancer was conserved in paired metastatic carcinoma, suggesting that allelic loss of these chromosome regions most likely occurs prior to the metastatic sequence. It is possible that allelic loss at these loci may be used as bladder cancer markers when the primary tumor of metastasis is unknown.

References

[1.] Greeenlee RT, Hill-Harmon MB, Murry T, et al. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.

[2.] Orlow I, Lacombe L, Hannon GI, et al. Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst. 1995;87:1524-1529.

[3.] Williamson MP, Elder PA, Shaw ME, et al. P16 (CDKN2) is a major deletion target at 9p21 in bladder cancer. Hum Mol Genet. 1995;4:1569-1577.

[4.] Sidransky D, Von Eschenbach A, Tsai YC, et al. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 1991;252:706-709.

[5.] Sarkis AS, Guido D, Cordon-Cardo C, et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst. 1993;85:53-59.

[6.] Esrig D, Elmajian D, Groshen S, et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med. 1994;331:1259-1264.

[7.] Esrig D, Spruck CH 3rd, Nichols PW, et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J Pathol. 1993;143:1389-1397.

[8.] Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/International Society of Urologic Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Am J Surg Pathol. 1998;22: 1435-1438.

[9.] Fleming ID, Cooper JS, Henson DE, et al. AJCC Cancer Staging Manual. Philadelphia, Pa: Lippincott Raven; 1997:241-246.

[10.] Zhuang Z, Bertheau P, Emmert-Buck M, et al. A microdissection technique for archival DNA analysis of specific cell populations in lesions [is less than] 1 mm in size. Am J Pathol. 1995;146:620-625.

[11.] Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from prostate cancer patients. J Natl Cancer Inst. 1997;90:233-237.

[12.] Park WS, Vortmeyer AO, Pack S, et al. Allelic deletion at chromosome 9p21 (p16) and 17p13 (p53) in microdissected sporadic dysplastic nevus. Hum Pathol. 1998;29:127-130.

[13.] Cheng L, Bostwick DG, Li G, et al. Allelic loss in the clonal evolution of prostate carcinoma. Cancer. 1999;85:2017-2022.

[14.] Bostwick DG, Shan A, Qian J, et al. Independent origin of multiple foci of prostate intraepithelial neoplasia (PIN): comparison with matched foci of prostate cancer. Cancer. 1998;83:1995-2002.

[15.] Sidransky EA, Frost P, von Eschenbach A, et al. Clonal origin of bladder cancer. N Engl J Med. 1992;326:737-740.

[16.] Miyao N, Tsai YC, Lerner SP, et al. Role of chromosome 9 in human bladder cancer. Cancer Res. 1993;53:4066-4070.

Accepted for publication May 15, 2001.

From the Department of Pathology, Indiana University School of Medicine, Indianapolis, Ind (Drs Cheng and Zhang); Bostwick Laboratories, Richmond, Va (Dr Bostwick); and the Molecular Pathogenesis Unit, Surgical Neurology Branch, National Cancer Institute, Bethesda, Md (Drs Li, Vortmeyer, and Zhuang).

Reprints: Liang Cheng, MD, Department of Pathology, UH 3465, Indiana University School of Medicine, 550 N University Blvd, Indianapolis, IN 46202 (e-mail: lcheng@iupui.edu).
COPYRIGHT 2001 College of American Pathologists
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2001 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Cheng, Liang; Bostwick, David G.; Li, Guang; Zhang, Shaobo; Vortmeyer, Alexander O.; Zhuang, Zhengpi
Publication:Archives of Pathology & Laboratory Medicine
Article Type:Statistical Data Included
Geographic Code:1USA
Date:Sep 1, 2001
Words:1770
Previous Article:Unexpected Autopsy Findings Arising From Postmortem Ocular Examination.
Next Article:Differential Expression of ras Signal Transduction Mediators in Verrucous and Squamous Cell Carcinomas of the Upper Aerodigestive Tract.
Topics:


Related Articles
Waterborne arsenic poses a cancer risk.
Introgen's gene therapy establishes basis for systemic treatment for metastatic cancer.
Cytokeratin 7 and Cytokeratin 20 in Primary Urinary Bladder Carcinoma and Matched Lymph Node Metastasis.
Aberrant Expression of Tumor Suppressor Proteins in the Ewing Family of Tumors.
FISH and genetics advance bladder-cancer diagnosis.
Nutraceutical: cultured milk.
Prostate cancer linked to defects in a single cell.
Gene that raises bladder cancer risk identified.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters